IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancerPuja Kachroo, Jay M. Lee|Journal of Experimental & Clinical Cancer Research|2013Cited by 80
Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.Aaron Lisberg, Steven M. Dubinett, Raymond J. Lim et al.|Journal of Clinical Oncology|2021Cited by 2
Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injectionsBin Liu, Steven M. Dubinett, Aaron Lisberg et al.|Cancer Research|2024Cited by 1